Shopping Cart
Remove All
Your shopping cart is currently empty
RTIOXA-43 is an OX2R/OX1R (orexin receptor) dual agonist that increases wakefulness and attenuates episodic sleep symptoms and is commonly used in studies related to narcolepsy and neural signaling.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $215 | - | In Stock | |
| 5 mg | $538 | - | In Stock | |
| 10 mg | $868 | - | In Stock | |
| 25 mg | $1,730 | - | In Stock | |
| 50 mg | $2,780 | - | In Stock | |
| 100 mg | $3,760 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $786 | - | In Stock |
| Description | RTIOXA-43 is an OX2R/OX1R (orexin receptor) dual agonist that increases wakefulness and attenuates episodic sleep symptoms and is commonly used in studies related to narcolepsy and neural signaling. |
| Targets&IC50 | OX2 recepter:24nM (EC50), OX1 recepter:24nM (EC50) |
| In vivo | Methods: Orexin modulation was induced in middle-aged (12 months) mice by peripheral injection of the small molecule orexin receptor agonist RTIOXA-133. Sleep-wake variables were measured by telemetry (after RTIOXA-43). Results: RTIOXA-43 improved wake time, reduced sleep duration (NREM and REM), and sleep/wake fragmentation. In addition, RTIOXA-43 improved sleep/wake quality by both reducing bout number and increasing bout duration. [1] |
| Molecular Weight | 663.79 |
| Formula | C37H37N5O5S |
| Cas No. | 2832067-72-6 |
| Smiles | COc1ccc(cc1S(=O)(=O)Nc1cccc(NCCNC(=O)c2cccc(C)c2)c1)-c1cccc(c1)C(=O)N(C)Cc1ccncc1 |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (120.52 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (4.97 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.